BCL2L1 and neoplasm: Moreover, we could also observe a significant increase in ∆% priming after incubating tumor cells with targeted agents, such as S63845, ABT-199, and SP2509 (Supplementary Fig. 5A) and we also identified possible anti-apoptotic adaptations to those treatments by BCL-xL and MCL-1 (Supplementary Fig. 5B) that we will further explore.